The treatment of diastolic dysfunction in a subject and, in particular, compositions for use and methods in treating diastolic dysfunction are disclosed. In one aspect, the disclosure provides a composition for use comprising a therapeutically effective amount of a substance that increases the level and/or activity of a crystalline protein in cardiomyocytes of the subject. In particular, the composition for use according to the disclosure comprises a therapeutically effective amount of the alpha B crystalline protein. It was found that the composition for use is capable of treating diastolic dysfunction and diastolic heart disease in subjects with failing hearts that have a higher cardiomyocyte stiffness than controls. Particularly, addition of alpha B crystalline reduced the higher stiffness of failing cardiomyocytes to the level observed in control cardiomyocytes.

FSP27 compositions and methods for treating cancers are described.

Disclosed are surprising new methods and kits for treating patients, particularly cancer patients, using bavituximab in combination therapies with immuno-oncology (IO) agents such as checkpoint inhibitor antibodies. The methods and kits are based on the surprising finding that human patients treated with bavituximab and checkpoint inhibitor antibodies have a statistically significant prolonged survival in controlled studies.

The disclosure relates to methods for treating cancers (e.g., cancers having a BRCA1 and/or BRCA2 mutation(s)) by administering to the subject an effective amount of a ubiquitin-specific protease 1 (USP1) inhibitor.

The present invention relates to Mitochondrial Fission Factor (MFF)-derived peptides or peptide mimetics and to methods of making MFF-derived peptides or peptide mimetics. Also provided are methods of treating a disease in a subject in need thereof, comprising administering to the subject an effective amount of a MFF-derived peptide or peptide mimetic.

The present invention relates to improved compounds for use in the treatment of diseases or conditions where the removal of senescent cells, scarred cells, and/or cancerous cells is beneficial, for example cancer. The invention also relates to methods of treating an individual suffering, or suspected of suffering, from a disease or condition wherein the removal of senescent cells, scarred cells, and/or cancerous cells is beneficial.

Compositions and methods are provided for the treatment or prevention of chemotherapy-induced peripheral neuropathy and hearing loss in a subject in need thereof. The methods involve administering to the subject a bclw protein, a BH4 domain-containing fragment thereof, or a bclw mimetic. Also provided are exemplary bclw mimetics.

Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.

A peptide is disclosed that has an amino acid sequence selected from X.sub.1-X.sub.2-X.sub.3-Gln-Leu-Met-Leu-Cys-Val-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 3), X.sub.1-X.sub.2-X.sub.3-Gln-X.sub.7-Met-X.sub.10-Cys-Val-X.sub.11-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 4), Ile-Ser-Phe-Gln-Leu-Met-Leu (SEQ ID NO: 5), Leu-Cys-Val-Leu-Asp-Tyr-Phe (SEQ ID NO: 6), X.sub.1-X.sub.2-X.sub.3-Gln-Leu-X.sub.8-Leu-X.sub.9-Val-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 7), X.sub.1-X.sub.2-X.sub.3-Gln-Leu-X.sub.8-Leu-X.sub.9-Val-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 7), X.sub.1-X.sub.2-X.sub.3-X.sub.12-Leu-Met-Leu-Cys-X.sub.13-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 10), Gln-X.sub.7-Met-X.sub.10-Cys-Val-X.sub.11 (SEQ ID NO: 11), Gln-Leu-X.sub.8-Leu-X.sub.9-Val-Leu (SEQ ID NO: 12), X.sub.12-Leu-Met-Leu-Cys-X.sub.13-Leu (SEQ ID NO: 13), Asp-Leu-Val-Ile-Ser-Phe-Gln-Leu-Met-Leu-Cys-Val-Leu-Asp-Tyr-Phe-Ile-Lys (SEQ ID NO: 14) and retro-inverso peptides thereof. The peptides disclosed herein may be used to treat liver cancer, lung cancer, breast cancer, pancreatic cancer, or brain cancer.

Compositions and methods are provided for the treatment or prevention of chemotherapy-induced peripheral neuropathy and hearing loss in a subject in need thereof. The methods involve administering to the subject a bclw protein, a BH4 domain-containing fragment thereof, or a bclw mimetic. Also provided are exemplary bclw mimetics.